Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Next Previous
Trial Profile

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Cabazitaxel (Primary) ; Capivasertib (Primary) ; Carboplatin (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Niraparib (Primary) ; Darolutamide; Radium 223 chloride
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ProBio

    • Most Recent Events

    • 11 Jan 2024 Number of treatment arms are increased from 6 to 8.
    • 24 Oct 2023 According to Results presented at the 48th European Society for Medical Oncology Congress, Enrollment in the experimental group was stopped when the Bayesian probability of superiority reached prespecified thresholds (''graduation'').
    • 24 Oct 2023 Results (n=219) assessing efficacy; progression-free survival, from following treatment arms (ARPi; abiraterone and enzalutamide and taxanes) and taxanes (docetaxel and cabazitaxel) presented at the 48th European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top